Key facts
- It has raised $787.0M; the latest was Later Stage VC ($787.0M) in Mar 2026.
- Notable investors include DST Global, INCE Capital, Dimension Capital Management, 21Vita, Harvest Miracle Capital — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Earendil Labs
- ·The full record, as it builds
Funding rounds
No funding rounds for Earendil Labs are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Earendil Labs
Developer of an artificial intelligence scientific computing platform intended for biotechnology firms, pharmaceutical companies, and research institutions. The company develops an AI drug development platform and a high-throughput antibody engineering experiment platform, thereby enabling scientific teams to decode complex protein interactions and design innovative treatments.
- Sector
- Healthcare
- HQ
- Middletown, DE, United States
- Founded
- 2021
- Website
- earendil.bio/
- Ownership
- Privately Held (backing)
Earendil Labs doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Earendil Labs shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Earendil Labs in its N-PORT filings yet. We sweep new filings monthly.